Telaprevir Under Study for HIV/HCV Coinfection
The investigational hepatitis C virus (HCV) protease inhibitor telaprevir -- the furthest along of the new directly targeted antiviral agents -- is now being tested in HIV/HCV coinfected individuals. The drug has demonstrated good antiviral activity in combination with pegylated interferon plus ribavirin in clinical trials of people with hepatitis C alone, and developer Vertex Pharmaceuticals plans to request FDA approval in the second half of this year. For further information, see "Open Clinical Trials."
Liz Highleyman (email@example.com) is a freelance medical writer based in San Francisco.
This article was provided by San Francisco AIDS Foundation. It is a part of the publication Bulletin of Experimental Treatments for AIDS. Visit San Francisco AIDS Foundation's Web site to find out more about their activities, publications and services.
Add Your Comment:
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)